Only with the ongoing Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity (SELECT) study (NCT03574597) will clinicians understand whether GLP-1 agonists (semaglutide) can reduce MACEs in obese patients with an established CV event (prior myocardial infarction, prior stroke, or peripheral arterial disease) without DM (118). This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.